London, United Kingdom – Aspen Pharma Ireland Limited (“Aspen”), a subsidiary of South African headquartered Aspen Pharmacare Holdings Limited, has entered into an exclusive licensing agreement (“Agreement”) with Norway-based Asamedic AS (“Asamedic”) for a new, patented, therapeutic option indicated for adults over 18 years of age for emergency treatment of suspected acute heart attack after contacting emergency services.
Under the agreement, Aspen will have exclusive rights to launch and commercialize the product in selected markets across Europe and the Middle East.
Daniel Vella Friggieri, Aspen Regional CEO Europe & Middle East, said, “The addition of this innovative formulation strengthens Aspen’s portfolio across Europe and the Middle East. We are proud to collaborate with Asamedic in reinforcing our commitment to expanding access to high quality, clinically relevant treatments and to supporting healthcare professionals with solutions that can make a critical difference in emergency care.”
Geir Ivar Westen, Asamedic CEO, commented, “We look forward to partnering with Aspen to bring our innovation to a broader international platform. Aspen’s long-standing expertise in acute and specialty care positions them as a strong partner for introducing this product to new markets.”
Firas Nabulsi: Head of Business Development & Marketing – Aspen Europe & Middle East
Daniel Vella Friggieri: Regional CEO
Aspen Europe & Middle East
Geir Ivar Westen: CEO – Asamedic
Tom Henrik Sundby: CFO – Asamedic
Halvor Sørbye: Investor – Asamedic
Issued by:
Firas Nabulsi, Aspen Europe & Middle East Head of Business Development and Marketing
Tel: +971 4 363 4932 | fnabulsi@ae.aspenpharma.com
On behalf of:
Daniel Vella Friggieri, Aspen Europe & Middle East Regional CEO
Tel: +971 4 363 4925 | dvella@ae.aspenpharma.com
About Aspen
Headquartered in Durban, South Africa, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets.
Aspen employs more than 9,500 employees at 66 established offices in over 48 countries and territories. The Group operates 24 manufacturing facilities across 15 sites and holds international manufacturing approvals from some of the world’s most stringent regulatory agencies.
Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and regional brands covering both hospital and consumer markets.
The Group’s key business segments are manufacturing and commercial pharmaceuticals, comprising injectable products, prescription, and OTC medicines.
For more information, visit www.aspenpharmaeme.com
About Asamedic
Asamedic is a Norwegian pharmaceutical company established in 2015 with the purpose of developing a drug against acute myocardial infarction. For more information, visit www.asamedic.com
